BlogHeader.png

Rigorous Integration in a Scalable Development and Manufacturing Enterprise to Support Continued Growth of Biopharmaceuticals


Screen_Shot_2016-09-22_at_3.08.36_PM.pngAs published in Pharma's Almanac Q2 2016.


The pharmaceutical and biopharmaceutical development and manufacturing market continue to experience significant expansion as the development of small molecule drugs and more complex large-molecule biologics rival for attention. Small and midsize pharma/biotech companies
are leading drug discovery and the engagement 
of contract development and manufacturing organizations (CDMOs) helps them to improve capabilities and enable companies to compete 
in this dynamic market.

Topics: Thought Leadership

Strengthening CDMOs to Meet Industry Needs For 2016 And Beyond

SStrengthening_CDMOs.png

As published in Pharma's Almanac Q1 2016.

Outsourcing companies pursuing an integrated services model aim to facilitate drug development and commercialization for drug sponsors by enabling them to work with a single partner for activities that often require multiple, specialized vendors.

With a single qualified partner, pharma companies can have simplified access to integrated analytical, development, manufacturing and packaging services, as well as a broad range of dose form manufacturing and similar services. Some contract development and manufacturing organizations (CDMOs) offer both API and drug product manufacture, while others offer formulation development and clinical supply manufacture to complement their commercial production operations. Regardless, the aim is to provide a seamless supply chain solution.

Topics: Thought Leadership

Feature in Manufacturing Chemist Pharma - Setting The Course For Success

Setting_the_Course_for_Success.pngValued at almost US$162 billion in 2014, the global pharmaceutical market is anticipated to have a compound annual growth rate (CAGR) of 9.4% reaching nearly $278 billion by 2020, according to Persistence Market Research. Driven in part by the increasing prevalence of chronic diseases and the ageing of the global population, this strong growth has brought numerous biologics effective at treating more widely spread conditions to a development and manufacturing peak. 

Topics: Thought Leadership

Bolstering Capabilities For Parenteral Drug Development and Manufacturing

Bolstering_Cap_Parenteral_Drug_Dev.png

As published in Pharma's Almanac Q4 2015.

As the pharmaceutical and biotechnology markets undergo significant changes, companies are relying more heavily on CROs and CMOs to provide the needed services, expertise, and technologies to help them favorably compete in a challenging marketplace. Contract service providers, in turn, are strengthening their capabilities to satisfy current demands, in some cases by coming together. An example is the recent combining of AAIPharma and Cambridge Major Laboratories, forming a full-service global CDMO supplying drug substance and drug product development, manufacturing, testing, and packaging services. This coupling also supports drug sponsors facing the escalating challenges of developing and manufacturing parenteral drug products.

Topics: Thought Leadership